Stroke Clinical Trial
Official title:
Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation: a Single-center, Retrospective, Long-term Real-world Study
Verified date | May 2017 |
Source | Shanghai 10th People's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study was to retrospectively analyse the efficacy and safety of LAA closure using the LAmbre in our center from April 2014 to November 2015.
Status | Completed |
Enrollment | 66 |
Est. completion date | May 1, 2017 |
Est. primary completion date | November 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Patient is =18 years of age; 2. Chronic atrial fibrillation =3 months; paroxysmal, persistent or permanent non-valvular AF; 3. CHADS2-VAS score 2 or higher; 4. Patient can understand the trial purpose, voluntarily join this clinical trial with informed consent; 5. Patient voluntarily completes the follow-up and follow-up inspection in accordance with the clinical trials process. Exclusion Criteria: • A. Clinical exclusion criteria 1. Presence of rheumatic, degenerative or congenital valvular heart diseases, 2. The diameter of left atrial =65 mm; 3. LAA size < 12mm or > 30 mm 4. Left atrium has been removed; 5. Heart transplantation patients; 6. Symptomatic patients with carotid artery disease (such as carotid stenosis = 50%); 7. Acute myocardial infarction or unstable angina; 8. Decompensated heart failure (New York Heart Association functional class III-IV); 9. Recent myocardial infarction (< 3 months); 10. Patients with an atrial septal defect or received an atrial septal occluder. The patient has an ablation procedure planned within 30 days of potential LAmbre Occluder implant 11. The patient has a planned cardioversion 30 days post implant of the LAmbre Occluder 12. Patient who after artificial mechanical heart valve replacement operation; 13. Uncontrolled Heart rate = 110 beats / min17) History stroke or TIA within 30 days; 14. Presence of complex aortic plaque(4mm) in ascending aorta; 15. Cardiac tumors or other malignancy with estimated life expectancy u less than 2 years; 16. Have thrombocytopenia (platelet «105 / µl) or anemia(Hb<10g/dl); 17. Women who is pregnancy or plan to pregnancy during the trial period; 18. Presence of active sepsis or endocarditis; 19. Patient participated in the other trials; 20. The investigators expect the patient not be able to complete the trial according to requirements. B. Esophageal ultrasonic exclusion criteria 1. LVEF=30%; 2. Presence of left atrial appendage thrombus; 3. High risk PFO patients(presence of atrial septal aneurysm); 4. Have obvious mitral valve stenosis (the area of mitral valve= 2 cm2); 5. Have obvious and unexplained pericardial effusion(=4 cm2). 6. Presence of complex aortic plague(=4 mm) in ascending aorta. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Shanghai 10th People's Hospital | Lifetech Scientific (Shenzhen) Co., Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ischemic stroke | Ischemic stroke | up to 5 years | |
Secondary | The composite safety and efficacy end-points | all-cause death, stroke, major bleeding, thromboembolism, device related severe complications | up to 5 years | |
Secondary | Successful sealing of the LAA | successful sealing around the device at the LAA orifice (residual jet flow of < 5 mm) as measured by transesophageal echocardiogram (TEE) at 6 months after device implantation | up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Recruiting |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Recruiting |
NCT05621980 -
Finger Movement Training After Stroke
|
N/A |